Adjei-Sowah Emmanuela, Chandrasiri Indika, Xiao Baixue, Liu Yuxuan, Ackerman Jessica E, Soto Celia, Nichols Anne E C, Nolan Katherine, Benoit Danielle S W, Loiselle Alayna E
bioRxiv. 2023 Nov 30:2023.11.29.569204. doi: 10.1101/2023.11.29.569204.
Tendon regeneration following acute injury is marred by a fibrotic healing response that prevents complete functional recovery. Despite the high frequency of tendon injuries and the poor outcomes, including functional deficits and elevated risk of re-injury, there are currently no pharmacological therapies in clinical use to enhance the healing process. Several promising pharmacotherapies have been identified; however, systemic treatments lack tendon specificity, resulting in poor tendon biodistribution and perhaps explaining the largely limited beneficial effects of these treatments on the tendon healing process. To address this major unmet need, we leveraged our existing spatial transcriptomics dataset of the tendon healing process to identify an area of the healing tendon that is enriched for expression of encodes tartrate-resistant acid phosphatase (TRAP), and we demonstrate robust TRAP activity in the healing tendon. This unexpected finding allowed us to refine and apply our existing TRAP binding peptide (TBP) functionalized nanoparticle (NP) drug delivery system (DDS) to facilitate improved delivery of systemic treatments to the healing tendon. To demonstrate the translational potential of this drug delivery system, we delivered the S100a4 inhibitor, Niclosamide to the healing tendon. We have previously shown that genetic knockdown of S100a4 enhances tendon healing. While systemic delivery of Niclosamide did not affect the healing process, relative to controls, TBP-NP delivery of Niclosamide enhanced both functional and mechanical outcome measures. Collectively, these data identify a novel tendon-targeting drug delivery system and demonstrate the translational potential of this approach to enhance the tendon healing process.
急性损伤后的肌腱再生受到纤维化愈合反应的影响,这会阻碍完全的功能恢复。尽管肌腱损伤的发生率很高且预后不佳,包括功能缺陷和再次受伤风险增加,但目前临床上尚无用于促进愈合过程的药物疗法。已经确定了几种有前景的药物疗法;然而,全身治疗缺乏肌腱特异性,导致肌腱生物分布不佳,这可能解释了这些治疗对肌腱愈合过程的有益作用在很大程度上有限的原因。为了满足这一尚未满足的主要需求,我们利用现有的肌腱愈合过程空间转录组学数据集,确定了愈合肌腱中一个富含编码抗酒石酸酸性磷酸酶(TRAP)的区域,并证明了愈合肌腱中存在强大的TRAP活性。这一意外发现使我们能够改进并应用现有的TRAP结合肽(TBP)功能化纳米颗粒(NP)药物递送系统(DDS),以促进全身治疗更好地递送至愈合中的肌腱。为了证明这种药物递送系统的转化潜力,我们将S100a4抑制剂氯硝柳胺递送至愈合中的肌腱。我们之前已经表明,基因敲低S100a4可促进肌腱愈合。虽然氯硝柳胺的全身递送不影响愈合过程,但与对照组相比,TBP-NP递送氯硝柳胺增强了功能和力学结果指标。总体而言,这些数据确定了一种新型的靶向肌腱的药物递送系统,并证明了这种方法在促进肌腱愈合过程中的转化潜力。